Identification of Serum Protein Markers for Breast Cancer Relapse With SELDI-TOF MS

8Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) was used to screen serum samples to identify protein markers for early breast cancer relapse. We collected 67 serum samples from patients with breast cancer (24 preoperative; 23 postoperative without breast cancer relapse; 20 postoperative with breast cancer relapse). Eight protein peaks varied between the presurgical group and the postsurgical group without breast cancer relapse; 4 protein peaks were differentially expressed between the postsurgical patients without relapse and patients with relapse. The peak at 3964 m/z dropped after surgery and rebounded after relapse (P < 0.01). These results indicate that there are differences in serum protein expression among the three different groups of patients. SELDI-TOF MS could be used to screen blood samples for the early detection of relapse in primary breast cancer patients. Specifically, protein peak at 3964 m/z is a potential biomarker for the detection of early breast cancer relapse. © 2011 Wiley-Liss, Inc.

Cite

CITATION STYLE

APA

Lei, L., Wang, X. J., Zheng, Z. G., Huang, J., Cao, W. M., Chen, Z. H., … Lu, H. Y. (2011). Identification of Serum Protein Markers for Breast Cancer Relapse With SELDI-TOF MS. Anatomical Record, 294(6), 941–944. https://doi.org/10.1002/ar.21399

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free